Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071582
Filing Date
2025-05-14
Accepted
2025-05-14 17:00:27
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eldn-20250331.htm   iXBRL 10-Q 2265809
2 EX-31.1 eldn-ex31_1.htm EX-31.1 16419
3 EX-31.2 eldn-ex31_2.htm EX-31.2 16710
4 EX-32.1 eldn-ex32_1.htm EX-32.1 10978
5 EX-32.2 eldn-ex32_2.htm EX-32.2 11058
  Complete submission text file 0000950170-25-071582.txt   9570918

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eldn-20250331.xsd EX-101.SCH 1238556
71 EXTRACTED XBRL INSTANCE DOCUMENT eldn-20250331_htm.xml XML 1858299
Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36620 | Film No.: 25946862
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)